• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Recent Advances in the Application of 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole (CAS: 2682112-53-2) in Chemical Biology and Pharmaceutical Research

The compound 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole (CAS: 2682112-53-2) has recently emerged as a significant building block in medicinal chemistry and chemical biology research. This silyl-protected oxazole derivative has shown remarkable versatility in organic synthesis and drug discovery applications. Recent studies have demonstrated its potential as a key intermediate in the synthesis of complex heterocyclic compounds with biological activity.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole as a precursor for developing novel kinase inhibitors. The silicon-protecting group was found to provide exceptional stability during multi-step synthetic routes while allowing for selective deprotection under mild conditions. This characteristic makes the compound particularly valuable for constructing complex molecular architectures in drug discovery programs.

Structural analysis of 2682112-53-2 reveals that the tert-butyldimethylsilyl (TBS) group significantly influences the electronic properties of the oxazole ring, as demonstrated by recent computational chemistry studies. Density functional theory (DFT) calculations published in early 2024 suggest that this modification enhances the compound's reactivity in palladium-catalyzed cross-coupling reactions, making it particularly useful for constructing drug-like molecules.

Recent applications in peptide mimetics development have highlighted the compound's potential in addressing challenging biological targets. A research team at MIT reported in Nature Chemical Biology (2024) the successful incorporation of 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole into peptidomimetic structures targeting protein-protein interactions. The silyl group was found to improve membrane permeability while maintaining target binding affinity.

The stability profile of 2682112-53-2 has been extensively characterized in recent pharmaceutical development studies. Accelerated stability testing under various pH and temperature conditions demonstrated that the TBS-protected oxazole maintains integrity in formulations better than its unprotected counterpart, suggesting advantages for prodrug development strategies.

Emerging research indicates potential applications of this compound in PROTAC (proteolysis targeting chimera) technology. The oxazole moiety serves as an effective linker between target-binding and E3 ligase-recruiting components, with the silyl group providing metabolic stability until reaching the target tissue. Several biotech companies have included derivatives of 2682112-53-2 in their preclinical pipelines for targeted protein degradation therapies.

Recent synthetic methodology developments have expanded the utility of 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole in parallel synthesis approaches. A 2024 publication in Organic Letters described a novel one-pot procedure for introducing diverse substituents at the 5-position of the oxazole ring while maintaining the TBS protection, enabling rapid generation of compound libraries for high-throughput screening.

From a safety perspective, recent toxicological evaluations of 2682112-53-2 and its derivatives have shown favorable profiles in preliminary studies. The compound appears to have low acute toxicity in rodent models, with good in vitro metabolic stability in human liver microsome assays. However, researchers caution that the optimal deprotection conditions need to be carefully controlled to avoid potential byproduct formation.

The commercial availability and scalability of 2-(tert-Butyl-dimethyl-silanyl)-4-methyl-oxazole have improved significantly in the past year, with multiple suppliers now offering GMP-grade material. This development has facilitated its adoption in larger-scale pharmaceutical projects and may accelerate the translation of research findings into clinical candidates.

Looking forward, the unique properties of 2682112-53-2 position it as a valuable tool for addressing current challenges in drug discovery, particularly in the areas of targeted protein degradation, covalent inhibitor design, and macrocyclic drug development. Ongoing research continues to explore novel applications of this versatile building block in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)